Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins

Infect Immun. 1995 May;63(5):1855-62. doi: 10.1128/iai.63.5.1855-1862.1995.

Abstract

Recombinant outer membrane proteins (Oprs) of Pseudomonas aeruginosa were expressed in Escherichia coli as glutathione S-transferase (GST)-linked fusion proteins. GST-linked Oprs F and I (GST-OprF190-350 [GST linked to OprF spanning amino acids 190 to 350] and GST-OprI21-83, respectively) and recombinant hybrid Oprs (GST-OprF190-342-OprI21-83 and GST-OprI21-83-OprF190-350) were isolated and tested for their efficacy as vaccines in immunodeficient mice. GST-OprF-OprI protected the mice against a 975-fold 50% lethal dose of P. aeruginosa. Expression of GST-unfused OprF-OprI failed in E. coli, although this hybrid protein has been expressed without a fusion part in Saccharomyces cerevisiae and used for immunizing rabbits. The immune rabbit sera protected severe combined deficient (SCID) mice against a 1,000-fold 50% lethal dose of P. aeruginosa. Evidence is provided to show that the most C-terminal part of OprF (i.e., amino acids 332 to 350) carries an important protective epitope. Opr-based hybrid proteins may have implications for a clinical vaccine against P. aeruginosa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bacterial / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Bacterial Proteins / genetics
  • Bacterial Proteins / immunology
  • Bacterial Proteins / therapeutic use*
  • Base Sequence
  • Epitope Mapping
  • Escherichia coli / genetics
  • Female
  • Immunosuppression Therapy
  • Immunotherapy*
  • Immunotherapy, Active
  • Immunotherapy, Adoptive
  • Lipoproteins / genetics
  • Lipoproteins / immunology
  • Lipoproteins / therapeutic use*
  • Mice
  • Mice, Inbred BALB C
  • Mice, SCID
  • Molecular Sequence Data
  • Porins / genetics
  • Porins / immunology
  • Porins / therapeutic use*
  • Pseudomonas Infections / mortality
  • Pseudomonas Infections / prevention & control*
  • Recombinant Fusion Proteins / therapeutic use
  • Saccharomyces cerevisiae / genetics
  • Survival Analysis

Substances

  • Antibodies, Bacterial
  • Antibodies, Monoclonal
  • Bacterial Proteins
  • Lipoproteins
  • Porins
  • Recombinant Fusion Proteins
  • outer membrane lipoprotein I, Bacteria